Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:

Fibromyalgia Trial Endpoints Should Be Validated In Real Time – FDA Cmte.

  • News

Executive Summary

Endpoints of fibromyalgia efficacy trials should be validated in "real time" with pain as one of the primary outcome measures, FDA's Arthritis Advisory Committee recommended June 23
Table

View full table

Advertisement

Related Content

Pink Sheet
Statistics Bedeviled Cymbalta Fibromyalgia NDA, Derail Chronic Pain Claim
Pink Sheet
Statistics Bedeviled Cymbalta Fibromyalgia NDA, Derail Chronic Pain Claim
Pink Sheet
Cymbalta Finds Divergent FDA, European Standards For Fibromyalgia Approval
Pink Sheet
Cymbalta Finds Divergent FDA, European Standards For Fibromyalgia Approval
Pink Sheet
Pfizer To Audit Managed Care Grants Under Lipitor “Best Price” Settlement
Pink Sheet
Pfizer To Audit Managed Care Grants Under Lipitor “Best Price” Settlement
Advertisement
Tags:
UsernamePublicRestriction

Register

PS042042

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By